Can Emerging Treatments Help Address Individual PN PatientBurden?
Dermatology
Prof. Sonja Ständer emphasizes the high patientburden of PN, and how this is influenced by patient needs and comorbidities. She discusses how emerging treatments are reducing patientburden.
Drs. Kathryn Peterson and Ikuo Hirano and Profs. Ingrid Terreehorst and Arjan Bredenoord highlight the impact and burden of EoE on the quality of life of patients.
The Cumulative Disease Burden of AD in Adult Patients
Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Eric Simpson discusses the array of allergic and non-allergic comorbidities that may impact adult patients with AD and how the cumulative burden of these comorbidities contributes to reduced quality of life. He goes on to discuss the potential for addressing the multimorbidities related to AD through early intervention before they have the opportunity to develop or progress.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.